The challenges of HIV vaccine development and testing

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 19, Issue 2 SPEC. ISS., 2005, Pages 277-291

  Burgers, Wendy A ^a   Williamson, Carolyn ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Efficacy trials; HIV diversity; HIV vaccine; Immune response

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; VIRUS VECTOR;

AFRICA; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DEVELOPING COUNTRY; DISEASE CONTROL; DNA VECTOR; DRUG EFFICACY; DRUG SAFETY; EPIDEMIC; FINANCIAL MANAGEMENT; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; IMMUNE RESPONSE; META ANALYSIS; MICROBIAL DIVERSITY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; SIDE EFFECT; SIMIAN IMMUNODEFICIENCY VIRUS; STRAIN DIFFERENCE; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS REPLICATION; VIRUS VIRULENCE;

EID: 15044352475     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpobgyn.2004.11.001     Document Type: Review

References (57)

1. UNAIDS. 2004 report on the global HIV/AIDS epidemic: 4th global report (available online at: www.unaids.org).
2. B. Korber B. Gaschen K. Yusim et al. Evolutionary and immunological implications of contemporary HIV-1 variation Br Med Bull 58 2001 19-42
3. B. Korber E.E. Allen A.D. Farmer G.L. Myers Heterogeneity of HIV-1 and HIV-2 AIDS 9 supplement A 1995 S5-S18
4. M. Altfeld T.M. Allen X.G. Yu et al. HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus Nature 420 2002 434-439
5. A. Ramos D.J. Hu L. Nguyen et al. Intersubtype human immunodeficiency virus type 1 superinfection following seroconversion to primary infection in two injection drug users J Virol 76 2002 7444-7452
6. W.P. Kong Y. Huang Z.Y. Yang et al. Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines J Virol 77 2003 12764-12772
7. E.A. Emini W.A. Schleif J.H. Nunberg et al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody Nature 355 1992 728-730
8. sm infection by passive immunisation in cynomolgus monkeys Nature 352 1992 436-438
9. J.R. Mascola M.G. Lewis G. Stiegler et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralising antibodies J Virol 73 1999 4009-4018
10. R.S. Veazey R.J. Shattock M. Pope et al. Prevention of virus transmission to macaque monkeys by vaginally applied monoclonal antibody to HIV-1 gp120 Nat Med 9 2003 343-346
11. D.D. Richman T. Wrin S.J. Little C.J. Petropoulos Rapid evolution of the neutralizing antibody response to HIV type 1 infection Proc Natl Acad Sci USA 100 2003 4144-4149
12. X. Wei J.M. Decker S. Wang et al. Antibody neutralization and escape by HIV-1 Nature 422 2003 307-312
13. P. Borrow H. Lewicki X. Wei et al. Antiviral pressure exerted by HIV-1 cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus Nat Med 3 1997 205-211
14. P.J.R. Goulder R.E. Phillips R.A. Colbert et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS Nat Med 3 1997 212-217
15. P. Klenerman Y. Wu R. Phillips HIV: Current opinion in escapology Curr Opin Microbiol 5 2002 408-413
16. M.B. Feinberg J.P. Moore AIDS vaccine models: Challenging the challenge viruses Nat Med 8 2002 207-210
17. P.D. Kwong M.L. Doyle D.J. Casper et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites Nature 420 2002 678-682
18. T.M. Allen T.U. Vogel D.H. Fuller et al. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen J Immunol 164 2000 4968-4978
19. R.R. Amara F. Villinger D. Altman et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine Science 292 2001 69-74
20. J.W. Shiver T.M. Fu L. Chen et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity Nature 415 2002 331-335
21. D.H. Barouch S. Santra J.E. Schmitz et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination Science 290 2000 486-492
22. T.C. Quinn M.J. Wawer N. Sewankambo et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1 N Engl J Med 342 2000 921-929
23. T.M. Allen D.H. O'Connor P. Jing et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viremia Nature 407 2000 386-390
24. D.H. Barouch J. Kunstman M.J. Kuroda et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes Nature 415 2002 335-339
25. D.R. Burton R.C. Desrosiers R.W. Doms et al. A sound rationale needed for Phase III HIV-1 vaccine trials Science 303 2004 316
26. http://www.iavireport.org/trialsdb/
27. http://www.hvtn.org/trials
28. M. McCarthy AIDS vaccine fails in Thai trial Lancet 362 2003 1728
29. D.R. Burton R.C. Desrosiers R.W. Doms et al. HIV vaccine design and the neutralizing antibody problem Nat Immunol 5 2004 233-236
30. P.B. Gilbert Y.-L. Chiu M. Allen et al. Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials Vaccine 21 2003 2933-2947
31. C. Van Wyk The participation of minors in preventive HIV research trials in South Africa: Legal and human rights considerations Med Law 22 2003 589-598
32. IAVI. A new access paradigm: Public sector action to assure swift, global access to AIDS vaccines. IAVI Access Project White paper. 2001; p. 36 (available online at: www.iaen.org/files.cgi/387_publicsector.pdf).
33. R.T. Gandhi B.D. Walker Promises and pitfalls in the reconstitution of immunity in patients who have HIV-1 infection Curr Opin Immunol 14 2002 487-494
34. M. Altfeld E.S. Rosenberg The role of CD4+ T helper cells in the cytotoxic T lymphocyte response to HIV-1 Curr Opin Immunol 12 2000 375-380
35. E.S. Rosenberg M. Altfeld S.H. Poon et al. Immune control of HIV-1 after early treatment of acute infection Nature 407 2000 523-526
36. F. Lori M.G. Lewis J. Xu Control of SIV rebound through structured treatment interruptions during early infection Science 209 2000 1591-1593
37. J.O. Kahn B.D. Walker et al. Acute human immunodeficiency virus type 1 infection N Engl J Med 339 1998 33-39
38. X. Jin D.E. Bauer S.E. Tuttleton et al. Dramatic rise in plasma viremia after CD8+ T cell depletion in simian immunodeficiency virus-infected macaques J Exp Med 189 1999 991-998
39. J.E. Schmitz M.J. Kuroda S. Santra et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes Science 283 1999 857-860
40. R.A. Koup J.T. Safrit Y.Z. Cao et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome J Virol 68 1994 4650-4655
41. P. Borrow H. Lewicki B.H. Hahn et al. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection J Virol 68 1994 6103-6110
42. S. Rowland-Jones J. Sutton K. Ariyoshi et al. HIV-specific cytotoxic T cells in HIV-exposed but uninfected Gambian women Nat Med 1 1995 59-64
43. S.L. Rowland-Jones T. Dong K.R. Fowke et al. Cytoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi J Clin Invest 102 1998 1758-1765
44. R. Kaul F.A. Plummer J. Kimani et al. HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1 resistant prostitutes in Nairobi J Immunol 164 2000 1602-1611
45. S.A. Migueles M.S. Sabbaghian W.L. Shupert et al. HLA B*701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long-term non-progressors Proc Natl Acad Sci USA 97 2000 2709-2714
46. T.M. Allen T.U. Vogel D.H. Fuller et al. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen J Immunol 164 2000 4968-4978
47. G. Franchini S. Gurunathan L. Baglyos et al. Poxvirus-based vaccine candidates for HIV: Two decades of experience with special emphasis on canarypox vectors Expert Rev Vaccines 3 supplement 1 2004 S75-S88
48. S. Crotty R. Andino Poliovirus vaccine strains as mucosal vaccine vectors and their potential use to develop an AIDS vaccine Adv Drug Deliv Rev 56 2004 835-852
49. J.W. Shiver T.M. Fu L. Chen et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity Nature 415 2002 331-335
50. N.F. Rose P.A. Marx A. Luckay et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants Cell 106 2001 539-549
51. C. Lorin L. Mollet F. Delebecque et al. A single injection of recombinant measles virus vaccines expressing human immunodeficiency (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV J Virol 78 2004 146-157
52. M. Kawahara A. Hashimoto I. Toida M. Honda Oral recombinant Mycobacterium bovis bacillus Calmette-Guerin expressing HIV-1 antigens as a freeze-dried vaccine induces long-term, HIV-specific mucosal and systemic immunity Clin Immunol 105 2002 326-331
53. D.T. Evans L.M. Chen J. Gillis et al. Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the Salmonella type III secretion antigen delivery system J Virol 77 2003 2400-2409
54. C. Peters X. Peng D. Douven et al. The induction of HIV Gag-specific CD8+ T cells in the spleen and gut-associated lymphoid tissue by parenteral or mucosal immunization with recombinant Listeria monocytogenes HIV Gag J Immunol 170 2003 5176-5187
55. K.Q. Xin T. Ooki H. Mizukami Oral administration of recombinant adeno-associated virus elicits human immunodeficiency virus-specific immune responses Hum Gene Ther 13 2002 1571-1581
56. T. Hanke C. Barnfield E.G. Wee et al. Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine J Gen Virol 84 2003 361-368
57. N.L. Davis A. West E. Reap et al. Alphavirus replicon particles as candidate HIV vaccines IUBMB Life 53 2002 209-211